Leland Stanford Junior University

Aravive Biologics, Inc.

Auckland Uniservices Limited

Via Pharmaceuticals, Inc.

Ruga Corporation

Raymond Tabibiazar

Amato J Giaccia

Mihalis S Kariolis

Yu Rebecca Miao

Douglas Scott Jones

Jennifer R Cochran

Connie L Sun

Michael Patrick Hay

Katherine Cynthia Fuh

Muriel Bonnet

Erinn Bruno Rankin

Adeoye Y Olukotun

Denise Chan

Edwin Lai

Olga Razorenova

Thomas Quertermous

John Irwin

Stanley G Rockson

Patrick Sutphin

Sandra Turcotte

Melisa Cooper

Patrick O'Connor

Compositions and methods are provided for treating fibrosis in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits AXL, MER or Tyro3 protein activity, for example by inhibition of the binding interaction between AXL, MER or Tyro3 and its ligand GAS6.

Antifibrotic activity of GAS6 inhibitor

Compositions and methods are provided for treating viral infection in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits AXL, MER or Tyro3 protein activity, for example by inhibition of the binding interaction between AXL, MER or Tyro3 and its ligand GAS6.

Antiviral activity of Gas6 inhibitor

Compositions and methods are provided for alleviating endometriosis, kidney disease, inflammatory disease and/or transplant rejection in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits AXL, MER or Tyro3 protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL, MER or Tyro3 and its ligand GAS6.

Inhibition of AXL/GAS6 signaling in the treatment of liver fibrosis

The present invention provides methods for inhibiting growth and proliferation of HIF pathway proficient cells by administering GLUT1 inhibitors of the invention to HIF pathway proficient cells.

Synthetic lethal targeting of glucose transport

The present invention identifies genes whose gene products are differentially expressed in lymphedema tissues, particularly cutaneous tissue involved in whole organ response to lymphedema. The invention provides methods for diagnosing or assessing an individual's susceptibility to lymphedema. Also provided are therapeutic methods for treating a patient or methods for prophylactically treating an individual susceptible to lymphedema. Additionally, the invention describes screening methods for identifying agents that can be administered to treat individuals that have or at risk of developing lymphedema.

Method for the treatment of acquired lymphedema

The method of treating patients be administering phenylalkyl N-hydroxurea derivatives for combating atherosclerotic plaque and cardiovascular diseases and compositions for this use.

Phenylalkyl N-hydroxyureas for combating atherosclerotic plaque

Growing community of inventors

Portola Valley, CA, United States of America

Raymond Tabibiazar